Added to YB: 2026-05-06
Pitch date: 2026-05-02
ABT [bullish]
Abbott Laboratories
-1.84%
current return
Author Info
No bio for this author
Company Info
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
Market Cap
$155.8B
Pitch Price
$89.18
Price Target
136.00 (+55%)
Dividend
2.82%
EV/EBITDA
15.11
P/E
25.06
EV/Sales
4.06
Sector
Health Care Equipment and Supplies
Category
value
The Healthcare Compounder I've Been Waiting to Buy – Now at a Deep Discount (Deep Dive) - Abbott Laboratories
ABT (new position): Healthcare compounder w/ $44B rev, 8% 10yr CAGR, 50+ yr div streak. FreeStyle Libre (17% rev) dominates global CGM at 57% share; expanding into Type 2 & OTC wellness via Lingo (400M addressable users). Structural growth in diabetes (13-15% CAGR) & cardiovascular devices (12-14% EP/MR). $21B Exact Sciences acquisition adds cancer screening (Cologuard) growing mid-teens but raises debt to 2.7x EBITDA. Risks: GLP-1 impact on CGM demand, Dexcom competition, Nutrition brand damage from NEC lawsuits, FreeStyle recall (7 deaths). Down 27% YTD to 16x P/E (10-yr low, 30% below median) despite 7-9% rev CAGR outlook through 2030. PT $136 (~20% IRR to 2028). Insiders buying.
Read full article (29 min)